Glucose to Lymphocyte Ratio and Cancer Prognosis
Author Information
Author(s): Liu Rongqiang, Shen Yankun, Cui Jiahui, Ma Wangbin, Wang Jianguo, Chen Chen, Wang Weixing
Primary Institution: Department of Hepatobiliary Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei, China
Hypothesis
The study aims to evaluate the prognostic value of glucose-to-lymphocyte ratio (GLR) in patients with solid tumors.
Conclusion
GLR can be used as an effective prognostic marker in patients with solid tumors.
Supporting Evidence
- High GLR was significantly associated with unfavorable overall survival and disease-free/progression-free survival.
- Subgroup analysis showed high GLR had better predictive value in liver, breast, and pancreatic cancers.
- GLR combines glucose levels and lymphocyte counts to reflect metabolic and immune status.
Takeaway
This study found that a high glucose-to-lymphocyte ratio means worse outcomes for cancer patients, helping doctors identify who might need more help.
Methodology
A meta-analysis of 22 studies was conducted to evaluate overall survival, disease-free survival, and recurrence-free survival using pooled hazard ratios.
Potential Biases
There was a degree of publication bias observed for overall survival.
Limitations
The included studies were mostly retrospective and conducted in Asia, with small sample sizes.
Participant Demographics
The studies included patients with various solid tumors, primarily from China, Korea, and Turkey.
Statistical Information
P-Value
HR:1.48 for overall survival, HR:2.20 for disease-free/progression-free survival
Confidence Interval
95% CI:1.34-1.63 for overall survival, 95% CI:1.66-2.92 for disease-free/progression-free survival
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website